Table 3 The Characteristics at the time of renal replacement therapy initiation in studies included in Meta-analysis
Author | Modality | Creatinine (mg/d L) | Urine output (ml/24 h) | APACHE II score | SOFA score | ||||
|---|---|---|---|---|---|---|---|---|---|
Early | Late | Early | Late | Early | Late | Early | Late | ||
Bouman | CVVH | NR | NR | NR | NR | EHV:23.5 (8.4) ELV:21.7 (5.5) | LLV:23.6 (8.3) | EHV:10.3 (2.8) ELV:10.1 (2.2) | LLV:10.6 (1.9) |
Durmaz | IHD | 3.1 (1.0) | 4.3 (1.1) | NR | NR | NR | NR | NR | NR |
Sugahara | CVVH | 2.9 (0.2) | 3.0 (0.2) | 29 (1)a | 18 (1)a | 19 (2) | 18 (3) | NR | NR |
Payen | CVVH | 2.1 (1.1) | 2.1 (1.3) | 1543 (209) | 1491 (242) | NR | NR | NR | NR |
Jamale | IHD | 7.4 (5.3) | 10.4 (3.3) | 429 (388) | 376 (350) | NR | NR | 7.6 (3.3) | 8.2 (3.1) |
Combes | CVVH | 1.7 (0.9) | 1.8 (0.9) | NR | NR | NR | NR | 11.5 (2.8) | 12 (2.9) |
Wald | IHD/CVVH/SLED | 3.7 (1.4) | 4.6 (2.2) | 400 (211–568) | 265 (80–755) | NR | NR | 12 (3.3) | 11.9 (2) |
Gaudry | IHD/CVVH | 3.3 (1.4) | 5.3 (2.3) | NR | 150 (50–600) | NR | NR | 10.9 (3.2) | 10.8 (3.1) |
Zarbock | CVVH | 1.9 (0.6) | 2.4 (1) | 445 (175–807.5) | 270 (112.5–670) | 30.6 (7.5) | 32.7 (8.8) | 15.6 (2.3) | 16 (2.3) |